Lurbinectedin-induced thrombocytopenia: the role of body surface area Apostolos PapachristosMark J. Ratain Editorial 01 April 2022 Pages: 573 - 575
Anti-drug antibodies in the current management of cancer Miguel BorregónKatherine MartínezVíctor Moreno Review Article 25 March 2022 Pages: 577 - 584
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer Carlos Fernández-TeruelSalvador FudioRubin Lubomirov Original Article Open access 05 November 2021 Pages: 585 - 594
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy Lin ZhaoHong ChenLu Xu Original Article 21 March 2022 Pages: 595 - 607
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy Natsuki FukudaYumiko AkamineMasatomo Miura Original Article 22 March 2022 Pages: 609 - 616
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors Sören BüskerWalter JägerAndreas Peyrl Original Article Open access 30 March 2022 Pages: 617 - 627
Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study Huybrecht T’jollynOliver AckaertNeeraj Agarwal Original Article 02 April 2022 Pages: 629 - 641
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma Reeder M. RobinsonAshton P. BasarNathan G. Dolloff Original Article Open access 05 April 2022 Pages: 643 - 653
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study Wenyuan XiongOrestis PapasouliotisPascal Girard Original Article Open access 06 April 2022 Pages: 655 - 669
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors Michelle L. GreenShu Chin MaJim J. Xiao Original Article 10 April 2022 Pages: 671 - 682
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer Jing XuYi GaoCongjian Xu Original Article Open access 13 April 2022 Pages: 683 - 695
Is age just a number? A population pharmacokinetic study of gemcitabine René J. BoosmanMarie-Rose B. S. CrombagAlwin D. R. Huitema Original Article 15 April 2022 Pages: 697 - 705
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model Jing JingYuan ChenRucha Sane Original Article Open access 15 April 2022 Pages: 707 - 720
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer Julia ManzoShannon PuhallaETCTN-8282 study team Original Article 18 April 2022 Pages: 721 - 735